REZDIFFRAREZDIFFRAREZDIFFRA

This indication is accredited under accelerated acceptance depending on improvement of NASH and fibrosis [see Clinical Experiments (14)]. Ongoing approval for this indicator may very well be contingent upon verification and outline of clinical advantage in confirmatory trials.This website is meant to be used by US healthcare industry experts only.